Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
BEAM-101 Efficacy: Achieved greater than 60% fetal hemoglobin (HbF) induction and reduced sickle hemoglobin (HbS) to less than 40% in patients. Neutrophil Engraftment: Median of 17 days post-treatment with BEAM-101. Platelet Engraftment: Median of 20 days post-treatment with BEAM-101. Safety Profile: BEAM-101 generally well tolerated; one patient death related to busulfan conditioning, not BEAM-101. ESCAPE Technology: Preclinical proof-of-concept achieved with non-genotoxic conditioning in non-human primates. Financial Position: Company remains in a strong financial position. Warning! GuruFocus has detected 3 Warning Sign with BEAM. Release Date: November 05, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Beam Therapeutics Inc ( NASDAQ:BEAM ) reported promising initial clinical data from their BEACON Phase 1/2 trial for BEAM-101, showing potential for meaningful clinical differentiation in treating sickle cel
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceGlobeNewswire
- Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]Seeking Alpha
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]Yahoo! Finance
BEAM
Earnings
- 11/5/24 - Miss
BEAM
Sec Filings
- 11/12/24 - Form SC
- 11/8/24 - Form 4
- 11/8/24 - Form SC
- BEAM's page on the SEC website